Name: Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) | Analysis of Revenues
Creator: Stock Analysis on Net

Analysis of Revenues

Revenues as Reported

Revenues as Reported

Download chart

Vertex Pharmaceuticals Inc., income statement, revenues

US$ in thousands

12 months ended:	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
TRIKAFTA/KAFTRIO	10,312,700)	10,238,600)	8,944,700)	7,686,800)	5,697,200)
ALYFTREK	837,800)	—)	—)	—)	—)
Other product revenues	820,100)	781,500)	924,500)	1,243,900)	1,876,200)
Product revenues, net	11,970,600)	11,020,100)	9,869,200)	8,930,700)	7,573,400)

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

Overall, product revenues demonstrate a consistent upward trajectory between 2021 and 2025, although the rate of growth fluctuates across individual product lines. The primary driver of this growth is TRIKAFTA/KAFTRIO, while other product revenues exhibit a declining trend before stabilizing.

TRIKAFTA/KAFTRIO Revenue: Revenue from TRIKAFTA/KAFTRIO increased substantially from US$5,697.2 million in 2021 to US$8,944.7 million in 2023, representing a significant growth phase. The growth rate decelerated somewhat in 2024, reaching US$10,238.6 million, and further slowed in 2025, with revenue at US$10,312.7 million. This suggests a maturing market for this product, with diminishing returns on revenue growth despite continued increases.
ALYFTREK Revenue: ALYFTREK generated no reported revenue in 2021, 2022, 2023, or 2024. Revenue began to materialize in 2025, reaching US$837.8 million. This indicates a recent product launch or market entry for ALYFTREK, contributing to overall revenue growth in the latest reported period.
Other Product Revenues: Other product revenues experienced a consistent decline from US$1,876.2 million in 2021 to US$781.5 million in 2024. A slight increase was observed in 2025, with revenue reaching US$820.1 million. This suggests a potential shift in product focus or declining sales of products within this category, with a possible stabilization in the most recent year.
Net Product Revenues: Net product revenues increased from US$7,573.4 million in 2021 to US$11,970.6 million in 2025. The growth was most pronounced between 2021 and 2024. While growth continued into 2025, the rate of increase slowed, reflecting the combined effects of decelerating TRIKAFTA/KAFTRIO growth and the initial contribution from ALYFTREK, alongside a slight recovery in other product revenues.

The company’s revenue profile is becoming increasingly concentrated in TRIKAFTA/KAFTRIO, with ALYFTREK emerging as a potentially significant contributor. The performance of other product revenues warrants continued monitoring to understand the factors driving its decline and the sustainability of the recent stabilization.

AI Ask an analyst for more

My previous chats

Add tokens

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?